31 research outputs found

    MD3: A NEW INDEX APPROACH TO MEASURE THE BENEFITS OF DELAYING THE PROGRESSION TO BLINDNESS

    Get PDF

    PMD28 CHALLENGES FOR MODEL-BASED ECONOMIC EVALUATIONS OF GLAUCOMA AND OCULAR HYPERTENSION TREATMENTS

    Get PDF

    PAE11 ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6 EUROPEAN COUNTRIES

    Get PDF

    Data for: Efficiency and Productivity of Cancer Care in Europe

    No full text
    Methods, Quantity Index and time series dat

    Data for: Efficiency and Productivity of Cancer Care in Europe

    No full text
    Methods, Quantity Index and time series dataTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV

    Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom

    No full text
    Aim: To determine utilisation patterns and calculate treatment failure and discontinuation rates in patients with open angle glaucoma treated in the United Kingdom with any of six groups of intraocular pressure (IOP) lowering agents. Methods: The UK General Practice Research Database was used to identify newly diagnosed (after 1 January 1997) open angle glaucoma patients who were naive to therapy with any of six index drug groups: carbonic anhydrase inhibitors, latanoprost, miotics, sympathomimetics, timolol, and other (non-timolol) β blockers. Analyses included drug treatment data for 1 year following diagnosis. Outcomes were (1) time to therapy failure, defined as either change in index drug (replacement or addition of therapy) or patient referral for surgery, and (2) time to therapy discontinuation, defined as either therapy failure or no refill of the index drug in a period twice that covered by the first prescription fill. Cox proportional hazard regression and Kaplan-Meier and life table methods were used to compare groups. Results: Among the 2001 eligible patients, a β blocker other than timolol was the most widely prescribed (42%), followed by timolol (32%), carbonic anhydrase inhibitors (10%), and latanoprost (7%). Compared to latanoprost, those treated with any alternative agent were significantly more likely to fail (p⩽0.005 for each comparison) and to discontinue (p⩽0.05 for each comparison) therapy. Failure rates ranged from 13% (latanoprost) to 45% (sympathomimetics), and discontinuation rates ranged from 30% (latanoprost) to 63% (miotics). Conclusion: Latanoprost treated patients demonstrated lower rates of therapy failure and therapy discontinuation compared with patients treated with other widely used IOP lowering medications, including β blockers
    corecore